The bio-incubator Eurasanté supports early-stage health startups, which aligns with the venture's pre-seed stage and biotech focus. However, the snippet mentions a digital therapeutic for insomnia, suggesting a broader health scope; the venture's AI-driven drug resistance prediction may fit if the incubator accepts computational biology tools. The geography is Hauts-de-France, not the venture's priority Île-de-France, slightly reducing fit.